Cargando…

Physiologically based pharmacokinetics and cancer risk assessment.

Physiologically based pharmacokinetic (PBPK) modeling involves mathematically describing the complex interplay of the critical physicochemical and biological determinants involved in the disposition of chemicals. In this approach, the body is divided into a number of biologically relevant tissue com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, M E, Krishnan, K
Formato:	Texto
Lenguaje:	English
Publicado:	1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1566886/ https://www.ncbi.nlm.nih.gov/pubmed/8187697

Ejemplares similares

Physiologically based pharmacokinetic analyses of simple mixtures.
por: Krishnan, K, et al.
Publicado: (1994)

Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.
por: Krewski, D, et al.
Publicado: (1994)

Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment
por: Taylor, Michael D., et al.
Publicado: (2012)

Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment
por: Mumtaz, Moiz, et al.
Publicado: (2012)

Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.
por: Gearhart, J M, et al.
Publicado: (1994)

The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment
por: Lu, Chensheng, et al.
Publicado: (2010)

Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids
por: Mallick, Pankajini, et al.
Publicado: (2020)

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations
por: Yu, Yanke, et al.
Publicado: (2021)

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach
por: Ezuruike, Udoamaka, et al.
Publicado: (2018)

Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.
por: Clewell, H J, et al.
Publicado: (2000)

A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.
por: Clewell, Harvey J, et al.
Publicado: (2002)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
por: Yellepeddi, Venkata K., et al.
Publicado: (2020)

Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment.
por: Haddad, S, et al.
Publicado: (1998)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments
por: Emond, Claude, et al.
Publicado: (2022)

Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments
por: Emond, Claude, et al.
Publicado: (2005)

Human physiologically based pharmacokinetic model for propofol
por: Levitt, David G, et al.
Publicado: (2005)

Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics
por: Zakaria, Zaril, et al.
Publicado: (2018)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
por: Jones, Hannah M., et al.
Publicado: (2019)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics
por: Lee, Myongjae, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures.
por: Krishnan, Kannan, et al.
Publicado: (2002)

Examination of Physiologically‐Based Pharmacokinetic Models of Rosuvastatin
por: Bowman, Christine M., et al.
Publicado: (2020)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
por: Yang, Xiaoxia, et al.
Publicado: (2015)

Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
por: Zhou, L, et al.
Publicado: (2015)

The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling
por: Ghoneim, Amira M, et al.
Publicado: (2020)

Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
por: Fendt, Rebekka, et al.
Publicado: (2021)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
por: Litjens, Carlijn H. C., et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children
por: Jiang, X-L, et al.
Publicado: (2013)

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
por: Le Merdy, Maxime, et al.
Publicado: (2020)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7ku83kf2cisc9n2bm4mnp9lerj